Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Hiroki IshiharaYuki NemotoKazutaka NakamuraHidekazu TachibanaTakashi IkedaHironori FukudaKazuhiko YoshidaHirohito KobayashiJunpei IizukaHiroaki ShimmuraYasunobu HashimotoTsunenori KondoToshio TakagiPublished in: Targeted oncology (2023)
The present study, using real-world data, provides evidence indicating the therapeutic benefit of ICI-based combination therapy over TKIs for advanced renal cell carcinoma was more statistically significant in the trial-ineligible population than in the trial-eligible population.
Keyphrases
- combination therapy
- renal cell carcinoma
- clinical trial
- phase iii
- phase ii
- study protocol
- open label
- randomized controlled trial
- cross sectional
- type diabetes
- electronic health record
- stem cells
- metabolic syndrome
- mesenchymal stem cells
- bone marrow
- glycemic control
- weight loss
- placebo controlled
- replacement therapy
- smoking cessation